X
NVAX icon

Xponance’s Novavax NVAX Stock Holding History

Xponance’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$137K Buy
14,562
+803
+6% +$7.2K ﹤0.01% 1680
2026
Q1 		$112K Buy
13,759
+1,968
+17% +$17.8K ﹤0.01% 1561
2025
Q4 		$79.2K Buy
11,791
+134
+1% +$1.01K ﹤0.01% 1490
2025
Q3 		$101K Buy
11,657
+58
+0.5% +$451 ﹤0.01% 1439
2025
Q2 		$73.1K Sell
11,599
-160
-1% -$1.06K ﹤0.01% 1436
2025
Q1 		$75.4K Sell
11,759
-72
-0.6% -$595 ﹤0.01% 1371
2024
Q4 		$95.1K Buy
+11,831
New +$114K ﹤0.01% 1370
2023
Q2 		– Sell
-12,458
Closed -$86.3K – 1280
2023
Q1 		$86.3K Buy
12,458
+1,222
+11% +$11.2K ﹤0.01% 1166
2022
Q4 		$116K Buy
+11,236
New +$198K ﹤0.01% 1150
2022
Q3 		– Sell
-9,218
Closed -$474K – 1208
2022
Q2 		$474K Buy
9,218
+523
+6% +$27.1K 0.01% 873
2022
Q1 		$640K Buy
8,695
+95
+1% +$8.47K 0.01% 794
2021
Q4 		$1.23M Buy
8,600
+238
+3% +$40.9K 0.02% 534
2021
Q3 		$1.73M Sell
8,362
-325
-4% -$71.6K 0.03% 378
2021
Q2 		$1.84M Buy
+8,687
New +$1.59M 0.03% 390
2020
Q3 		– Sell
-2,686
Closed -$224K – 1037
2020
Q2 		$224K Buy
+2,686
New +$103K 0.01% 930

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Xponance's NVAX Position: Q2 2026 in Review

Xponance increased its Novavax (NVAX) stake by 5.8% in Q2 2026, buying an estimated $7.2K and bringing the position to 14,562 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #1680.

Xponance first reported a position in NVAX in Q2 2020 and has held it in 15 quarters since. The position peaked at $1.84M in Q2 2021. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Xponance held 14,562 shares of Novavax worth $137K as of Q2 2026.
  • Xponance bought 803 Novavax shares in Q2 2026, an estimated $7.2K.
  • Novavax made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1680 holding.
  • Xponance first reported a position in Novavax in Q2 2020 and has held it in 15 quarters since.
  • Xponance's Novavax position peaked at $1.84M in Q2 2021.
  • 266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.